

CURRICULUM VITAE ANNALISA BRUNO

PERSONAL INFORMATIONS

Surname: Bruno
Name: Annalisa
E-mail: annalisa.bruno@unicamillus.org
Work address:

Department of Innovative Technologies in Medicine & Dentistry and CAST (Center of Advanced Studies and Technology), "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini, 31, 66100, Chieti, Italy.

ACADEMIC POSITION

July 2023 to date: Full-time Assistant Professor - PHARMACOLOGY, CLINICAL PHARMACOLOGY AND PHARMACOGNOSY - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara

EDUCATION AND TRAINING

March 2014: Ph.D. in Medical-Surgery, Clinical, and Experimental Sciences achieved at the "G. D'Annunzio" University of Chieti.

Title of the thesis: "Variability in the response to cyclooxygenase inhibitors: development of biomarkers of drug response and safer therapeutics" (Supervisor: Prof. Paola Patrignani)

July 2002: Post-graduated advanced course "Hygiene and Technology of Food", Department of General and Environmental Physiology, University of Napoli Federico II, Napoli, Italy

June 2002: Qualifying examination for Practising Pharmacy, University of Napoli Federico II, Napoli, Italy

July 2001: Master Degree in Pharmaceutical Chemistry and Technology, University of Napoli Federico II, Italy. Score: 109/110.

Title of the thesis: "Effects of leptin on inflammatory enzymes of astrocytes stimulated with cytokines", Laboratory of Pharmacology, University of Napoli Federico II (Tutor: Prof. Raffaele Di Carlo).

PROFESSIONAL EXPERIENCES

July 2023 to date: Researcher with full-time fixed-term employment (art. 24 paragraph 3 letter B) of the Italian Law 240/2010 (JUNIOR), S.S.D. BIO/14 PHARMACOLOGY S.C. 05/G1 PHARMACOLOGY, CLINICAL PHARMACOLOGY AND PHARMACOGNOSY at the Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, and Center for Advanced Studies and Technology (CAST).

November 2020-June 2023: Researcher with full-time fixed-term employment (art. 24 paragraph 3 letter A) of the Italian Law 240/2010 (JUNIOR), S.S.D. BIO/14 PHARMACOLOGY S.C. 05/G1 PHARMACOLOGY, CLINICAL PHARMACOLOGY AND PHARMACOGNOSY at the Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti and Center for Advanced Studies and Technology (CAST).

March 2014-February 2020: Post-doc Research Fellow at the Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy to realize the project entitled "Platelets in colorectal cancer development" at the Center for Advanced Studies and Technology (CAST, ex CeSI-MeT), in the Laboratory of Systems Pharmacology and Translational Therapeutics (SPaTT Lab), directed by Prof. Patrignani.

January 2010-October 2013: Ph.D. course in Medical-Surgical Sciences, Clinical and Experimental Science at the "G. d'Annunzio" University of Chieti (Supervisor: Prof. Paola Patrignani) to realize the research project "Variability in the response to cyclooxygenase inhibitors: development of biomarkers of drug response and safer therapeutics"

July 2008-December 2009: Post-doc Research Fellow [Assegno di Ricerca (ex art. 51, sesto comma della Legge 27 dicembre 1997, n. 449) - SSD BIO/14] at the Department of Medicine and Aging Sciences, University "G. d'Annunzio" of Chieti, Italy (Supervisor: Prof. Paola Patrignani) to realize the project entitled "Development of genetic and biochemical markers predictive of responses to non-steroidal inflammatory drugs (NSAIDs)"

September 2005-June 2008: Junior Research Associate at In Vivo Pharmacology Laboratory, Dompé pha.r.ma. s.p.a. Research & Manufacturing, L'Aquila, Italy, to realize the project entitled: "Characterization of selected molecules in experimental animal models for the preclinical development of allosteric non-competitive inhibitors of CXCR1/2 receptor for the treatment of chronic inflammation and neoplastic diseases".

July 2004-June 2005: Research Fellow at the Animal Care Unit of the Institute of Pharmacological Sciences "Consorzio Mario NegriSud", Santa Maria Imbaro (CH).

July 2002-June 2004: Research Fellow at the Animal Care Unit of the Institute of Pharmacological Sciences "Consorzio Mario NegriSud", Santa Maria Imbaro (CH), Italy, funded by MUIR (Ministry of Instruction, University and Research), within a two-year, High-Level Course of post-graduate training on "Expert of pharmacological techniques" S209-P/F- Decreto n. 629/97- Pratica n. 68679/488 RIC San Paolo IMI)

October 1999-July 2001: Thesis internship at the Department of Pharmacology, School of Pharmacy, University of Napoli Federico II, under the supervision of Prof. Raffaele Di Carlo to realize the experimental degree thesis, entitled "Effects of leptin on inflammatory enzymes of astrocytes stimulated with cytokines."

SCIENTIFIC INTERESTS

I has a long experience in interdisciplinary translational research projects characterized by the use of different model systems, including mammalian cells and mice, but also humans. I contributed to the development of quantitative approaches, based on the use of mass spectrometry (lipidomics and proteomics) to predict therapeutics and adverse effects of drugs, including antithrombotic, antiinflammatory and anticancer drugs.

The main topic of my research is the study of the mechanisms of platelet activation in cardiovascular disease and cancer with a particular interest in the cellular events regulating platelet microparticles shedding. In particular, I studied the mechanisms underlying the ability of platelets

to promote inflammation, tumorigenesis, and metastatization. These studies are relevant to elucidate the chemopreventive effects of anti-platelet drugs, including low-dose aspirin.

Another topic of my research activity is related to the development of biomarkers for the study of variability in the response to nonsteroidal anti-inflammatory drugs (NSAIDs) and to the study of the effects of new anti-inflammatory agents designed to reduce the toxicity of coxibs and traditional NSAIDs).

PARTICIPATION TO NATIONAL AND INTERNATIONAL RESEARCH PROJECTS

- **2002-2005:** I contributed as *Staff Scientist* to a project funded by FIRB [protocol number RBNE01X3NB, 2002-2006, PI: Daniela Corda (Istituto di Ricerche Farmacologiche Mario NegriSud , Santa Maria Imbaro, Chieti) . My participation to this project is demonstrated by the following publication:

Bruno A, Rossi C, Marcolongo G, Di Lena A., Venzo A, Berrie CP, Corda D. Selective in vivo anti-inflammatory action of the galactolipid monogalactosyldiacylglycerol. *European Journal of Pharmacology* 2005, 524:159-68

- **2009:** I contributed as *Staff Scientist* to a project funded by the pharmaceutical company Angelini Pharma SpA, S.Palomba-Pomezia (Rome), Italy [grant number: 092FM04248; PI: Paola Patrignani; “G.d’Annunzio” University of Chieti-Pescara]. **Project title:** "Caratterizzazione dell'effetto inibitorio di nuovi composti sull'attività di PGE sintetasi in sangue intero umano". My participation to this project is demonstrated by the following publication:

Bruno A*, Di Francesco L*, Coletta I, Mangano G, Alisi MA, Polenzani L, Milanese C, Anzellotti P, Ricciotti E, Dovizio M, Di Francesco A, Tacconelli S, Capone ML, Patrignani P. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. *Biochem Pharmacol.* 2010;79(7):974-81 (***contributed equally, first author**)

- **2010:** I contributed as *Staff Scientist* to a project funded by the pharmaceutical company Angelini Pharma SpA, S.Palomba-Pomezia (Rome), Italy [grant number: 092FM10094; PI: Paola Patrignani; “G.d’Annunzio” University of Chieti-Pescara]. **Project title:** "Pharmacological characterization of AF3485 towards COX-isozyme and 5-lipoxygenase activities in vitro". My participation in this project is demonstrated by the following publication:

Di Francesco L,* **Bruno A**,*Ricciotti E, Tacconelli S, Dovizio M, Guillem-Llobat P, Alisi MA, Garrone B, Coletta I, Mangano G, Milanese C, FitzGerald GA and Patrignani P. Pharmacological characterization of the microsomal prostaglandin E2 synthase-1 inhibitor AF3485 in vitro and in vivo. *Frontiers in Pharmacology*, 2020, 11:374. (***contributed equally, first author**)

- **2010-2011:** I contributed as *Staff Scientist* to a project funded by the pharmaceutical company Rottapharm SpA (Monza) Italy [PI: Paola Patrignani; “G.d’Annunzio” University of Chieti-Pescara]. **Project title:** "Effects of novel diarylpyrrole derivative on cyclooxygenase -1 and cyclooxygenase-2 activities in human whole blood assays in vitro". My participation in this project is demonstrated by the following publication:

Biava M, Porretta GC, Poce G, Battilocchio C, Alfonso S, Rovini M, Valenti S, Giorgi G, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Papa G, Ghelardini C, Di Cesare Mannelli L, Giordani A, Anzellotti P, **Bruno A**, Patrignani P, Anzini M. Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties. *J Med Chem.* 2011; 54: 7759-7771.

- **2008-2012:** I contributed as *Staff Scientist* to a project funded by AIRC, Associazione Italiana per la Ricerca Sul Cancro [Grant IG-1262, 2005-2007, PI: Paola Patrignani. **Project title:** “Determinants of colorectal adenoma recurrence in patients with FAP in response to celecoxib”]. My participation in this project is demonstrated by the following publication: Dovizio M*, Tacconelli S*, Ricciotti* E, **Bruno A**, Maier TJ, Anzellotti P, Di Francesco L, Sala P, Signoroni S, Bertario L, Dixon DA, Lawson JA, Steinhilber D, FitzGerald GA, Patrignani P. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. *J Pharmacol Exp Ther.* 2012;341(1):242-50. (***contributed equally, second author**)
- **2012-2014:** I contributed as *Staff Scientist* to a project funded by AIRC, Associazione Italiana per la Ricerca Sul Cancro [Grant IG-12111, PI: Paola Patrignani, University of Chieti]. External collaborators were: Dan A Dixon (University of Kansas, Kansas City, USA), Dieter Steinhilber (University of Frankfurt, Germany), Ying Yu (Chinese Academy of Sciences, Shanghai, China). **Project title:** “Platelets in colorectal cancer development.” My participation in this project is demonstrated by 4 publications:
 - i) Guillem-Llobat P*, Dovizio M*, **Bruno A***, Ricciotti E, Cufino V, Sacco A, Grande R, Alberti S, Arena V, Cirillo M, Patrono C, FitzGerald GA, Steinhilber D, Sgambato A, Patrignani P. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. *Oncotarget.* 2016 31;7(22):32462-77(***contributed equally, first author**)
 - ii) Di Francesco L, Dovizio M, Trenti A, Marcantoni E, Moore A, O'Gaora P, McCarthy C, Tacconelli S, **Bruno A**, Alberti S, Gizzo S, Nardelli GB, Orso G, Belton O, Trevisi L, Dixon DA, Patrignani P. Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells. *Br J Pharmacol.* 2015;172(18):4575-4587.
 - iii) Patrignani P, Sacco A, Sostres C, **Bruno A**, Dovizio M, Piazuolo E, Di Francesco L, Contursi A, Zucchelli M, Schiavone S, Tacconelli S, Patrono C, Lanas A. Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. *Clin Pharmacol Ther.* 2017;102(1):52-61.
 - iv) Saul MJ*, Baumann I*, **Bruno A***, Emmerich AC, Wellstein J, Ottinger SM, Contursi A, Dovizio M, Donnini S, Tacconelli S, Raouf J, Idborg H, Stein S, Korotkova M, Savai R, Terzuoli E, Sala G, Seeger W, Jakobsson PJ, Patrignani P, Suess B, Steinhilber D. miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. *FASEB J.* 2019;33(6):6933-6947(***contributed equally, first author**)
- **2013-2016:** I contributed as *Staff Scientist* to a PRIN project, funded by Ministero dell'Istruzione, dell'Università e Della Ricerca (MIUR) [protocol number 2010FHH32M, 2010-2011, PI: Paola Patrignani, “G.d'Annunzio” University of Chieti-Pescara). **Project title:** “A translational medicine research programme exploring early events in cancer development: the role of platelets in intestinal tumorigenesis.” My participation to this project is demonstrated by 3 publications:
 - i) Guillem-Llobat P*, Dovizio M*, **Bruno A***, Ricciotti E, Cufino V, Sacco A, Grande R, Alberti S, Arena V, Cirillo M, Patrono C, FitzGerald GA, Steinhilber D, Sgambato A, Patrignani P. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. *Oncotarget.* 2016 31;7(22):32462-77(***contributed equally, first author**)
 - ii) Di Francesco L, Dovizio M, Trenti A, Marcantoni E, Moore A, O'Gaora P, McCarthy C, Tacconelli S, **Bruno A**, Alberti S, Gizzo S, Nardelli GB, Orso G, Belton O, Trevisi L, Dixon DA, Patrignani P. Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells. *Br J Pharmacol.* 2015;172(18):4575-4587.
 - iii) Patrignani P, Sacco A, Sostres C, **Bruno A**, Dovizio M, Piazuolo E, Di Francesco L, Contursi A, Zucchelli M, Schiavone S, Tacconelli S, Patrono C, Lanas A. Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. *Clin Pharmacol Ther.* 2017;102(1):52-61.
- **2017-2020:** I contributed as *Staff Scientist* to a project funded by AIRC, Associazione Italiana per la Ricerca Sul Cancro [Grant IG-20365, PI: Paola Patrignani, “G.d'Annunzio” University of Chieti-Pescara]. **Project title:** “Extracellular vesicles in colorectal cancer:

diagnostic and therapeutic implications.” My participation in this project is demonstrated by 2 publications:

- i) Grande R, Dovizio M, Marcone S, Szklanna PB, **Bruno A**, Ehardt HA, Cassidy H, Ní Áinle F, Caprodossi A, Lanuti P, Marchisio M, Mingrone G, Maguire PB, Patrignani P. Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. *Front Pharmacol.* 2019;10:7.
 - ii) Sacco A*, **Bruno A***, Contursi A, Dovizio M, Tacconelli S, Ricciotti E, Guillem-Llobat P, Salvatore T, Di Francesco L, Fullone R, Ballerini P, Arena V, Alberti S, Liu G, Gong Y, Sgambato A, Patrono C, FitzGerald G, Yu Y, Patrignani P. Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. *J Pharmacol Exp Ther.* 2019;370:416–426(***contributed equally, first author**)
 - iii) Tacconelli S*, Contursi A*, Falcone L, Mucci M, D'Agostino I, Fullone R, Sacco A, Zucchelli M, **Bruno A**, Ballerini P, Dovizio M, Patrignani P. Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems. *Biochemical Pharmacology.* 2020; 178:114094(***contributed equally**)
- **2018-2020:** I contributed as *Staff Scientist* to a project funded by Cancer Research UK, Aspirin for Cancer Prevention Group, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London (London, UK). **Project title:** “Understanding the mechanisms of aspirin chemoprevention of cancer through population research” [Codice Progetto: C569/A24991; Principal Investigator: Jack Cuzick (Queen Mary University of London), Co-Principal Investigator: Paola Patrignani (Università “G. d’Annunzio” di Chieti). My participation in this project is demonstrated by the following publications:
 - i) Sacco A*, **Bruno A***, Contursi A, Dovizio M, Tacconelli S, Ricciotti E, Guillem-Llobat P, Salvatore T, Di Francesco L, Fullone R, Ballerini P, Arena V, Alberti S, Liu G, Gong Y, Sgambato A, Patrono C, FitzGerald G, Yu Y, Patrignani P. Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. *J Pharmacol Exp Ther.* 2019;370:416–426(***contributed equally, first author**)
 - ii) Tacconelli S*, Contursi A*, Falcone L, Mucci M, D'Agostino I, Fullone R, Sacco A, Zucchelli M, **Bruno A**, Ballerini P, Dovizio M, Patrignani P. Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems. *Biochemical Pharmacology.* 2020; 178:114094(***contributed equally**)
 - **2014-2019:** I participated as *Staff Scientist* to the realization of projects funded by “ex 60% -MIUR” [PI: Paola Patrignani, “G.d’Annunzio” University of Chieti-Pescara].

PARTICIPATION IN INTERNATIONAL AND NATIONAL CONFERENCES

Oral communications

- 1) **Bruno A.**, Coletta I., Polezani L., Milanese C., Anzellotti P., Ricciotti E., Dovizio M., Patrignani P. AF3442, a novel inhibitor of human mPGES-1, does not redirect prostanoid metabolism in human whole blood in vitro. XXXIV Congresso Nazionale della Società Italiana di Farmacologia. Rimini, 14-17 October 2009
- 2) **Bruno A.** Differential roles of mPGES-1 in experimental inflammatory colitis. Frankfurt International Research School for Translational Biomedicine “Roles of eicosanoids in Biology and Medicine”. Obergurgl, Austria. 10-14 April, 2011
- 3) **Bruno A.**, Dovizio M., Alberti S., Sacco A., Schiavone S., Sgambato A., Maier T.J., Steinhilber D. and Patrignani P. Inhibition of cyclooxygenase-1-dependent signaling between platelets and HT29 colon cancer cells by aspirin prevents upregulation of Twist-1 and repression of E-cadherin. XXXVI Congresso Nazionale della Società Italiana di Farmacologia. Torino, 23-26 October, 2013
- 4) **Bruno A.** Role of prostanoids in dextran-sodium-sulphate-induced colitis in mice. European PhD School on Bioactive Lipids. Pescara, 23-27 November, 2014

- 5) **Bruno A.** Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Seminario CEA. CeSI-MeT, Università "G. D'Annunzio" di Chieti-Pescara, 20 April, 2016
- 6) **Bruno A.** Role of platelets in fibroblast phenotype. Gruppo di studio sulle piastrine (GSP) 2016. Padova, 2-4 October, 2016
- 7) **Bruno A** e Contursi A. miR-574-5p contributes to human lung cancer cell growth by inducing microsomal prostaglandin E synthase-1-dependent prostaglandin E₂ biosynthesis. Seminario CEA. CeSI-MeT, Università "G.D'Annunzio" di Chieti-Pescara, 9 May 2017
- 8) **Bruno A.**, Alberti S, Zhang Q, Munch G, Yu Y, Patrignani P. The novel antiplatelet agent Revacept mitigates injury-induced vascular neointima hyperplasia. XVIII riunione del Gruppo di Studio delle Piastrine. 1-3 October 2017, Milano
- 9) **Bruno A.**, Alberti S, Tacconelli S, Zhang Q, Munch G, Yu Y, Patrignani P. The novel antiplatelet agent Revacept mitigates injury-induced vascular neointima hyperplasia. Monothematic Conference: "Cardiovascular diseases: from population to basic science - searching for new therapeutic targets", Napoli 26-27 September, 2018
- 10) **Bruno A.** Off-target effects of the mPGES1 inhibitor AF3485 both *in vivo* and *in vitro*. Resolution of inflammation: mechanisms, mediators & biomarkers". Pescara, 13-16 November, 2018
- 11) **Bruno A.**, Contursi A, Dovizio M, Tacconelli S, Ricciotti E, Guillem-Llobat P, Salvatore T, Di Francesco L, Fullone R, Ballerini P, Arena V, Alberti S, Liu G, Gong Y, Sgambato A, Patrono C, FitzGerald GA, Yu Y, and Patrignani P. Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 39°Congresso Nazionale della Società Italiana di Farmacologia. Firenze, 20-23 November, 2019
- 12) **Bruno A.** Suppression of Intestinal Polyposis in ApcMin/+ mice by the specific deletion of cyclooxygenase-1 (COX-1) in megakaryocytes/platelets. AsCaP Meeting, 11-12 October, 2021
- 13) **Bruno A.** "Specific deletion of cyclooxygenase-1 (COX-1) in megakaryocyte/platelets reduces intestinal polyposis in ApcMin/+ mice". 41°Congresso Nazionale della Società Italiana di Farmacologia. Roma, 16-19 november 2022

Poster

- 1) **Bruno A.**, Mosca M., Buanne P., Del Bufalo D., Desideri M., Giorgini S., Ruco L., Allegretti M., Gloaguen I., Bizzarri C., Melillo G., Bertini R., Zupi G."Antimetastatic effect of a novel non competitive CXCR1/CXCR2 inhibitor in human melanoma". XXXIV Congresso Nazionale della Società Italiana di Farmacologia, 6-9 June 2007, Cagliari
- 2) **Bruno A.**, Coletta I., Milanese C., Anzellotti P., Ricciotti E., Dovizio M. and Patrignani P. "AF3442, a novel inhibitor of human mPGES-1, does not redirect prostanoid metabolism in human whole blood *in vitro*". 11th International Winter Eicosanoid Conference, 8-11 March 2009, Baltimore, USA
- 3) **Bruno A.** Role of prostanoids in inflammatory bowel diseases (IBDs): new insights from microsomal prostaglandin E synthase-1 knockout mice. XIV Seminario Nazionale per Dottorandi in Farmacologia e Scienze Affini. Certosa di Pontignano (Siena). 20-23 September, 2010
- 4) **Bruno A.** Differential roles of microsomal Prostaglandin E Synthase-1 in murine colitis. XV Seminario Nazionale per Dottorandi in Farmacologia e Scienze Affini nell'ambito del XXXV Congresso Nazionale della Società Italiana di Farmacologia. Bologna, 14-17 October 2011
- 5) **Bruno A.**, Saul M.J., Baumann I., Contursi A., Dovizio M., Donnini S., Tacconelli S., Raouf J., Idborg H., Stein S., Korotkova M., Savai R., Salvatore T., Terzuoli E., Jakobsson P.J., Suess B., Steinhilber D., Patrignani P. Over-expression of miR-574 increases tumor growth in xenograft of

human lung cancer cells via prostaglandin E2. XXXVIII Congresso Nazionale della Società Italiana di Farmacologia, Rimini 25-28 October 2017

MEMBERSHIP TO SCIENTIFIC SOCIETY

2009-present: Member of the Italian Society of Pharmacology (SIF)

ACADEMIC MEMBERSHIPS

June 2019-present: Scientific Member of the 'Committee for Animal Care' [Organismo per il Benessere Animale (OpBA)] of "G. d'Annunzio" University of Chieti-Pescara (D.R. n 886/2019-Titolo VI-Class 8-Prot. N.40722 del 10-06-2019)

TEACHING EXPERIENCE

Teaching positions at the "G. d'Annunzio" University of Chieti-Pescara

AY 2020-21; 2021-22 – PSYCHOPHARMACOLOGY- Course of ELEMENTS OF HUMAN PHYSIOLOGY, NEUROPSYCHOPHARMACOLOGY AND PSYCHIATRY- Degree Course of Psychological Sciences and Techniques - CFU: 2.0.

AY 2022-23 and 2023-24 - FUNDAMENTALS OF NEUROPSYCHOPHARMACOLOGY - Course of ELEMENTS OF HUMAN PHYSIOLOGY, NEUROPSYCHOPHARMACOLOGY AND PSYCHIATRY, Degree Course of PSYCHOLOGICAL SCIENCES AND TECHNIQUES - CFU: 4.0

AY 2021-22, 2022-23 and 2023-24: THIRD YEAR SEMINAR (Title: Fetal toxicity and teratogenesis of drugs) – Degree Course of OBSTETRICS (QUALIFYING FOR THE HEALTH PROFESSION OF MIDWIFE) – CFU: 2.0

AY 2022-23 and 2023-24: FUNDAMENTALS OF PSYCHOPHARMACOLOGY - Course of BIOMEDICAL MECHANISMS OF MENTAL ACTIVITY, Degree Course of CLINICAL AND HEALTH PSYCHOLOGY - CFU:3.0

AY 2022-23 and 2023-24: PHARMACOLOGY IN EMERGENCIES AND CRITICAL CARE - Course of NURSING SCIENCES IN EMERGENCY AND CRITICAL AREA. Degree Course of NURSING (QUALIFYING FOR THE HEALTH PROFESSION OF NURSE) - CFU:1.0

AY 2022-23 and 2023-24: PHARMACOLOGY AND THERAPY - Course of NURSING SCIENCES IN THE MEDICAL AND SURGICAL AREA, Degree Course of NURSING (QUALIFYING FOR THE HEALTH PROFESSION OF NURSE) - CFU:1.0

EDITORIAL ACTIVITY

Associate Editor for Inflammation Pharmacology (Frontiers in Pharmacology).

Reviewer for the following peer-reviewed journals: Advances in Pharmacological Sciences, Biochemical Pharmacology, European Journal of Medicinal Chemistry, Journal of Physiology and Pharmacology

2010-present: Associate Editor for *Frontiers in Inflammation Pharmacology* (IF: 3.8)

2019-present: Special Issue Editor for *Cancers* (IF: 6.13)(*Special Issue Title: Platelets and cancer*)

2012: Co-author of the book chapter entitled "Mode of action of aspirin as a chemopreventive agent" published in *Prospects for Chemoprevention of Colorectal Neoplasia. Recent Results in Cancer Research*, edited by Chan A., Detering E, vol 191. Springer, Berlin, Heidelberg

2016: Co-author of the book chapter entitled "Molecular and Experimental Basis for COX Inhibition in Cancer" published in *NSAIDs and Aspirin*, edited by Angel Lanas, Springer.

2016: Co-author of the book chapter entitled "Acetylsalicylic acid as platelet aggregation inhibitor" published in PHARMAKON. 2017; 5:32-40 Edited by Avoxa-Mediengruppe Deutscher Apotheker GmbH(*First author*)

PUBLICATIONS IN PEER-REVIEWED JOURNALS

My scientific production is documented by:

44 publications in Peer-Reviewed Journals [14 as first author and 5 as second author]:

24 publications are *research articles* [8 as first author and 3 as second author]

19 publications are *review articles* [5 as first author and 2 as second author]

1 publication is a *book chapters* [1 as first author].

Bibliometric indicators (Source: Scopus)

- Total number of citations: 1452

- Average impact factor per publication: 5.91 (current); 5.01 (year of publication);

- H-index: 23

List of publications (Scopus)

1) **Bruno A**, Rossi C, Marcolongo G, Di Lena A., Venzo A, Berrie CP, Corda D. Selective in vivo anti-inflammatory action of the galactolipid monogalactosyldiacylglycerol. *European Journal of Pharmacology* 2005, 524:159-68 (*Research article*) (*First author*)

2) Rossi C, Hess S, Eckl RW, Di Lena A, **Bruno A**, Thomas O, Poggi A. Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice. *J. Thromb. Haemost.* 2006, 4:608-613 (*Research article*)

3) Vitagliano D., Portella G., Troncone G., Francione A., Rossi C., **Bruno A.**, Giorgini A., Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. *Oncogene.* 2006, 25: 5467-5474 (*Research article*)

4) **Bruno A***, Di Francesco L*, Coletta I, Mangano G, Alisi MA, Polenzani L, Milanese C, Anzellotti P, Ricciotti E, Dovizio M, Di Francesco A, Tacconelli S, Capone ML, Patrignani P. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes

in vitro. *Biochem Pharmacol.* 2010, 79: 974-81. *contributed equally (*Research article*)(*First author*)

5) Patrignani P, Tacconelli S and **Bruno A**. Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. *Frontiers in Pharmacology.* 2010; 1: 2 (*Opinion article*) (*Last author*)

6) Anzellotti P, Capone ML, Jeyam A, Tacconelli S, **Bruno A**, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. *Arthritis Rheum.* 2011, 63: 850-859 (*Research article*)

7) Biava M, Porretta GC, Poce G, Battilocchio C, Alfonso S, Rovini M, Valenti S, Giorgi G, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Papa G, Ghelardini C, Di Cesare Mannelli L, Giordani A, Anzellotti P, **Bruno A**, Patrignani P, Anzini M. Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties. *J Med Chem.* 2011; 54: 7759-7771 (*Research article*)

8) Patrignani P, Tacconelli S **Bruno A**, Sortes C and Lanas A. Managing adverse effect of nonsteroidal anti-inflammatory drugs. *Expert Rev. Clin. Pharmacol.* 2011, 4: 605-621 (*Review*)

9) Marcantoni E, Di Francesco L, Dovizio M, **Bruno A**, Patrignani P. Novel insights into the vasoprotective role of heme oxygenase-1. *Int J Hypert.* 2012; 2012:127910(*Review*)

10) Dovizio M*, Tacconelli S*, Ricciotti E*, **Bruno A**, Maier TJ, Anzellotti P, Di Francesco L, Sala P, Signoroni S, Bertario L, Dixon DA, Lawson JA, Steinhilber D, FitzGerald GA, Patrignani P. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. *J Pharmacol Exp Ther.* 2012, 341: 242-250 (*Research article*) (*Second author*) *contributed equally.

11) **Bruno A**, Dovizio M, Tacconelli S, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. *Best Pract Res Clin Gastroenterol.* 2012, 26:e1-e13 (*Review*) (*First author*)

12) Vitale P, Tacconelli S, Perrone MG, Malerba P, Simone L, Scilimati A, Lavecchia A, Dovizio M, Marcantoni E, **Bruno A**, Patrignani P. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. *J Med Chem.* 2013; 56:4277-99 (*Research article*)

13) Dovizio M, **Bruno A**, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. *Recent Results in Cancer Research* 2013; 191:39-65 (*Review*) (*Second author*)

14) Dixon DA, Blanco FF, **Bruno A**, Patrignani P. Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia. *Recent Results in Cancer Research* 2013; 191:7-37 (*Review*)

- 15) Bruno A**, Tacconelli S, Patrignani P. Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. *Basic Clin Pharmacol Toxicol.* 2014, 114:56-63 (*Review*) (*First author*)
- 16)** Guillem-Llobat P, Dovizio M, Alberti S, **Bruno A**, Patrignani P. Platelets, cyclooxygenases, and colon cancer. *Semin Oncol.* 2014; 41:385-96 (*Review*)
- 17)** Patrignani P, Tacconelli S, **Bruno A**. Gut microbiota, host gene expression, and aging. *J Clin Gastroenterol.* 2014;48:S28-31 (*Review*)
- 18)** Di Francesco L, Dovizio M, Trenti A, Marcantoni E, Moore A, O'Gaora P, McCarthy C, Tacconelli S, **Bruno A**, Alberti S, Gizzo S, Nardelli GB, Orso G, Belton O, Trevisi L, Dixon DA, Patrignani P. Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells. *Br J Pharmacol.* 2015;172: 4575–4587 (*Research article*)
- 19)** Guillem-Llobat P,* Dovizio M,* **Bruno A**,* Ricciotti E, Cufino V, Sacco A, Grande R, Alberti S, Arena V, Cirillo M, Patrono C, FitzGerald GA, Steinhilber D, Sgambato A, Patrignani P. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. *Oncotarget.* 2016; 7:32462-77. *contributed equally (*Research article*) (*First author*)
- 20) Bruno A**, Dovizio M, Patrignani P. Molecular and Experimental Basis for COX Inhibition in Cancer" d in "NSAIDs and Aspirin", pp 175-201 (2016). Editor Angel Lanas, Springer. (*Book chapter*) (*First author*)
- 21)** Patrignani P, Sacco A, Sostres C, **Bruno A**, Dovizio M, Piazzuelo E, Di Francesco L, Contursi A, Zucchelli M, Schiavone S, Tacconelli S, Patrono C, Lanas A. Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. *Clin Pharmacol Ther.* 2017; 102:52-61 (*Research article*)
- 22)** Tacconelli S, **Bruno A**, Grande R, Ballerini P, Patrignani P. Nonsteroidal anti-inflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts. *Expert Opin Drug Saf.* 2017;16:791-807 (*Review*) (*Second author*) **I**
- 23)** Ballerini P, Dovizio M, **Bruno A**, Tacconelli S, Patrignani P. P2Y12 receptors in tumorigenesis and metastasis. *Frontiers in Pharmacology.* 2018; 9: 66 (*Review*)
- 24)** Tacconelli S, Dovizio M, Di Francesco L, Meneguzzi A, D'Agostino I, Evangelista V, Manarini S, Capone ML, Grossi L, Porreca E, Di Febbo C, **Bruno A**, Ballerini P, Levantesi G, Fava C, Minuz P, Patrignani P. Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. *Clin Pharmacol Ther.* 2018; 104:111-119 (*Research article*)
- 25)** Dovizio M*, **Bruno A***, Contursi A, Grande R, Patrignani P. Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications. *Cancer Metastasis Rev.* 2018 ;37:455-467 *contributed equally (*Review*) (*First author*)
- 26) Bruno A**, Dovizio M, Tacconelli S, Contursi A, Ballerini P, Patrignani P. Antithrombotic Agents and Cancer. *Cancers.* 2018;10(8).*contributed equally (*Review*) (*First author*)

- 27) Contursi A, Grande R, Dovizio M, **Bruno A**, Fullone R, Patrignani P. Platelets in cancer development and diagnosis. *Biochem Soc Trans.* 2018;46:1517-1527 (*Review*)
- 28) Grande R, Dovizio M, Marcone S, Szklanna PB, **Bruno A**, Ehardt HA, Cassidy H, Ní Áinle F, Caprodossi A, Lanuti P, Marchisio M, Mingrone G, Maguire PB, Patrignani P. Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. *Front Pharmacol.* 2019;10:7 (*Research article*)
- 29) Saul MJ*, Baumann I*, **Bruno A***, Emmerich AC, Wellstein J, Ottinger SM, Contursi A, Dovizio M, Donnini S, Tacconelli S, Raouf J, Idborg H, Stein S, Korotkova M, Savai R, Terzuoli E, Sala G, Seeger W, Jakobsson PJ, Patrignani P, Suess B, Steinhilber D. miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. *FASEB J.* 2019; 33(6):6933-6947. *contributed equally (*Research article*) (*First author*)
- 30) Sacco A*, **Bruno A***, Contursi A, Dovizio A, Tacconelli S, Ricciotti E, Guillem-Llobat P, Salvatore T, Di Francesco L, Fullone R, Ballerini P, Arena V, Alberti S, Liu G, Gong Y, Sgambato A, Patrono C, FitzGerald GA, Yu Y, and Patrignani P. Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. *J Pharmacol Exp Ther.* 2019; 370:416–426. *contributed equally. (*Research article*) (*First author*)
- 31) Di Francesco L*, **Bruno A***, Ricciotti E, Tacconelli S, Dovizio M, Guillem-Llobat P, Alisi MA, Garrone B, Coletta I, Mangano G, Milanese C, FitzGerald GA and Patrignani P. Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo. *Front Pharmacol.* 2020; 11: 374. *contributed equally (*Research article*) (*First author*)
- 32) Tacconelli S, Contursi A, Falcone L, Mucci M, D'Agostino I, Fullone R, Sacco A, Zucchelli M3, **Bruno A**, Ballerini P, Dovizio M, Patrignani P. Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems. *Biochem Pharmacol.* 2020;178: 114094. (*Research article*)
- 33) Tacconelli S, Fullone R, Dovizio M, Pizzicoli G, Marschler S, **Bruno A**, Zucchelli M, Contursi A, Ballerini P, Patrignani P. Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis. *Biochim Biophys Acta Mol Cell Biol Lipids.* 2020; 1865:158804 (*Research article*)
- 34) Alberti S*, Zhang Q*, D'Agostino I*, **Bruno A**, Tacconelli S, Contursi A, Guarnieri S, Dovizio M, Falcone L, Ballerini P, Münch G, Yu Y, Patrignani P. The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia. *Sci Rep.* 2020; 10:21420. *contributed equally (*Research article*) (*Second author*)
- 35) Consalvi S, Poce G, Ghelardini C, Di Cesare Mannelli L, Patrignani P, **Bruno A**, Anzini M, Calderone V, Martelli A, Testai L, Giordani A, Biava M. Therapeutic potential for coxibs-nitric oxidereleasing hybrids in cystic fibrosis. *Eur J Med Chem.* 2021; 15; 210:112983. (*Review*)
- 36) D'Agostino I*, Tacconelli S*, **Bruno A***, Contursi A, Mucci L, Hu X, Xie Y, Chakraborty R, Jain K, Sacco A, Zucchelli M, Landolfi R, Dovizio M, Falcone L, Ballerini P, Hwa J, Patrignani P.

Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained. *Pharmacol Res.* 2021; 170: 105744. *contributed equally (*Research article*) (*First author*)

37) Ballerini P, Contursi A, **Bruno A**, Mucci M, Tacconelli S, Patrignani P. Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. *Front Pharmacol.* 2022; 13:838079. (*Review*)

38) Rovati G, Contursi A, **Bruno A**, Tacconelli S, Ballerini P, Patrignani P. Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis. *Cells.* 2022; 11:725. (*Review*)

39) Contursi A, Tacconelli S, Hofling U, **Bruno A**, Dovizio M, Ballerini P, Patrignani P. Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk. *Biochem Pharmacol.* 2022;205: 115252. (*Review*)

40) **Bruno A***, Contursi A*, Tacconelli A, Sacco A, Hofling U, Mucci M, Lamolinara A, Del Pizzo A, Ballerini P, Di Gregorio P, Yu Ying, Patrignani P. The specific deletion of cyclooxygenase-1 in megakaryocytes/platelets reduces intestinal polyposis in *Apc^{Min/+}* mice. *Pharmacological Research* 2022; 185: 106506. *contributed equally (*Research article*) (*First author*)

41) Hofling U*, Tacconelli*, Contursi A*, **Bruno A**, Mucci M, Ballerini P, Cohen S and Patrignani P. Characterization of the acetylation of cyclooxygenase-isozymes and targeted lipidomics of eicosanoids in serum and colon cancer cells by the new aspirin formulation IP1867B versus aspirin in vitro. *contributed equally. *Front Pharmacol* 2022; 13:1070277. (*Research article*)

42) Contursi A*, Fullone R*, Szklanna-Koszalinska P, Marcone S, Lanuti P, Taus F, Meneguzzi A, Turri G, Dovizio M, **Bruno A**, Pedrazzani C, Tacconelli S, Marchisio M, Ballerini P, Minuz P, Maguire P and Patrignani P. Tumor-educated platelet extracellular vesicles: proteomic profiling and crosstalk with colorectal cancer cells. *Cancers* 2023, 15: 350; <https://doi.org/10.3390/cancers15020350> (*Research article*) *contributed equally.

43) Lanas A, Tacconelli S, Contursi A, Piazzuelo E, **Bruno A**, Ronci M, Marcone S, Dovizio M, Sopena F, Falcone L, Milillo C, Mucci M, Ballerini P, Patrignani P. Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients. *Cancers (Basel).* 2023;15: 2457. (*Research article*)

44) **Bruno A**, Tacconelli S, Contursi A, Ballerini P, Patrignani P. Cyclooxygenases and platelet functions. *Adv Pharmacol.* 2023;97:133-165. (*Review*) (*First author*)

CONGRESS PROCEEDINGS

1) Rossi C, Hess S, Eckl RW, Di Lena A, **Bruno A**, O. Thomas, A. Poggi. Effect of MCM09, an active site directed inhibitor of Factor Xa, on B16-BL6 melanoma in mice. 1st ISC International Conference on Cancer Therapeutics, Molecular Targets, Pharmacology and Clinical Applications. Firenze, 19-21 Febbraio 2004. *Journal of Chemotherapy*, 16 (suppl. 4), 2004

2) Rossi C, Hess S, Eckl RW, Di Lena A, **Bruno A**, Thomas O, Poggi A. Effect of MCM09, an Active Site Directed Inhibitor of Factor Xa, on B16-BL6 Melanoma Experimental Lung Colonies. Third International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo 14-16 Ottobre, 2005] *Hematologica Reports* 1(9): 111 (ISSN 1824-9337) 2005

- 3) Patrignani P, Dovizio M, Tacconelli S, **Bruno A**, Sciulli MG, Sala P, Signoroni S, Bertario L, Dixon DA, Lawson J, FitzGerald GA, Capone ML. Effects of Celecoxib on Prostanoid Biosynthesis and Inflammatory and Angiogenic Biomarkers in Patients with Familial Adenomatous Polyposis. *ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY*, 29 (7), E101-E101, 2009
- 4) Capone ML, Anzellotti P, Tontodonati P, Grossi L, **Bruno A**, Tacconelli S, Di Francesco L, Dovizio M, Salvatore T, Patrignani P. Naproxen interferes with the irreversible inhibition of platelet Cox-1 by aspirin in healthy subjects. *Clinical Pharmacology & Therapeutics*. 87:S25, 2010
- 5) Sostres C, Tacconelli S, **Bruno A**, Di Francesco L, Arruebo M, Jimene P, Patrignani P, Lanas A. Sa1962-Determinants of eicosanoid generation and inhibition in human gastric mucosa in vitro. *Gastroenterology*, Volume 144, Issue 5, S-345, 2013
- 6) Patrignani P, Sacco A, Sostres A, **Bruno A**, Dovizio A, Piazzuelo E, Di Francesco L, Schiavone S, Tacconelli S, Ferrandez A, Patrono C, Lanas A. 1068-Direct evidence for long-lasting acetylation of cyclooxygenase-1 associated with reduction of colorectal mucosa prostaglandin E2 Levels and Ribosomal Protein S6 phosphorylation by low-dose aspirin in subjects undergoing colorectal cancer Screening. *Gastroenterology* 150: S211, 2016.

LEAVE PERIOD

From December 22, 2011, to November 23, 2012, I had a maternity leave period.

"Autorizzo al trattamento dei dati personali contenuti nel presente curriculum ai sensi del Codice in materia di protezione dei dati personali (d.lgs 196/03 e successive modificazioni ed integrazioni)"

Chieti, 30 novembre 2023

Annalisa Bruno

